News Room

Polfa Kutno Acquires Leading Antibiotic from Eli Lilly

April 28, 2003

Philadelphia, PA - Polfa Kutno purchased the rights to the antibiotic CECLOR® (cefaclor) for the territory of Poland from Eli Lilly - Polfa Kutno announced on April 28, 2003.

With Plexus Ventures' support, the transaction successfully concluded a negotiation that lasted less than 6 months. Rights to the trademark CECLOR® as well as manufacturing, marketing and distribution know-how in Poland will be transferred to Polfa Kutno immediately. CECLOR® sales in 2002 amounted to nearly US$ 10 million. The purchase of this asset is partly self-financed and partly coming from a line of credit.

In the year 2002 Polfa Kutno achieved sales of PLN 211,2 million (about US$ 56 Million) and over PLN 23 million (US$ 6 Million) of net profit.

About Plexus Ventures

Plexus Ventures, founded in 1990, provides strategic advice, business development and alliance management services to clients in the pharmaceutical, biotechnology and drug delivery industries worldwide. Plexus Ventures assists its clients in the areas of in-licensing, out-licensing, acquisitions, divestitures and strategic partnerships. With offices in Frankfurt, Indianapolis, London, Los Angeles, Milan, Philadelphia, Tokyo and Warsaw, Plexus Ventures possesses the capabilities to effectively serve clients in the United States, Europe and Asia. Plexus Ventures is both well-known and well respected by leading research-based pharmaceutical companies worldwide. For further information, please consult: